AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8608205 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation for one night
Number of subjects: 121
Study 8608205 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day treatment with chlormadinone acetate (CMA)
Number of subjects: 121
Study 8608205 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day treatment with acetazolamide (ACET)
Number of subjects: 121
Study 8608205 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 121
Study 2583007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (8 educational lessons)
Number of subjects: 752
Study 2583007 — intervention group
Group type: COMPARATOR
Intervention: Control group (no activities)
Number of subjects: 752
Study 1102231 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam 20 mg
Number of subjects: 74
Study 1102231 — intervention group
Group type: COMPARATOR
Intervention: Morphine 12 mg
Number of subjects: 74
Study 31468673 — intervention group
Group type: EXPERIMENTAL
Intervention: Biyeom-go treatment >3 times daily for a total of 4 weeks
Number of subjects: 58
Study 29908675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa powder (30 g) and dark chocolate (50 g) daily for 1 week
Number of subjects: 100
Study 29908675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27166583 — intervention group
Group type: COMPARATOR
Intervention: Nutrition only
Number of subjects: 290
Study 27166583 — intervention group
Group type: COMPARATOR
Intervention: Nutrition + CBT
Number of subjects: 290
Study 27166583 — intervention group
Group type: COMPARATOR
Intervention: CBT only
Number of subjects: 290
Study 27166583 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 290
Study 24351886 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 87
Study 24351886 — intervention group
Group type: COMPARATOR
Intervention: Thiamylal
Number of subjects: 87
Study 22120130 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 group (6 g/d fish oil; n = 91)
Number of subjects: 178
Study 22120130 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 87)
Number of subjects: 178
Study 20621377 — intervention group
Group type: COMPARATOR
Intervention: One-year intervention group (OIG, n=23)
Number of subjects: 123
Study 20621377 — intervention group
Group type: COMPARATOR
Intervention: Two-year intervention group (TIG, n=25)
Number of subjects: 123
Study 20621377 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n=75)
Number of subjects: 123
Study 18416220 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-balanced ultrafiltration (ZBUF) (50 ml/kg) and conventional ultrafiltration (CUF)
Number of subjects: 20
Study 18416220 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrafiltration (CUF) only
Number of subjects: 20
Study 15050249 — intervention group
Group type: EXPERIMENTAL
Intervention: ThinOptX IOL
Number of subjects: 28
Study 15050249 — intervention group
Group type: COMPARATOR
Intervention: AcrySof IOL
Number of subjects: 28
Study 11856139 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic antireflux surgery
Number of subjects: 230
Study 11856139 — intervention group
Group type: COMPARATOR
Intervention: Open antireflux surgery
Number of subjects: 230
Study 9639442 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically excised CNV specimens from patients with ARMD
Number of subjects: 160
Study 9639442 — intervention group
Group type: COMPARATOR
Intervention: Surgically excised CNV specimens from non-ARMD patients
Number of subjects: 160
Study 8073431 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 50-150 mg for five consecutive days in each treatment cycle
Number of subjects: 608
Study 2800898 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% cyclosporin gel
Number of subjects: 20
Study 2800898 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 20
Study 1090222 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraldehyde (10 ml rectally every 30 minutes)
Number of subjects: 34
Study 1090222 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg then 5 mg intravenously every 5 minutes)
Number of subjects: 34
Study 1090222 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (intramuscularly)
Number of subjects: 34
Study 1090222 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraldehyde (rectally)
Number of subjects: 34
Study 1090222 — intervention group
Group type: COMPARATOR
Intervention: Paraldehyde
Number of subjects: 34
Study 1090222 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 34
Study 31094261 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimum Power Load (OPL) training (squat + hip thrust exercises at maximum power output)
Number of subjects: 0
Study 31094261 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric Training (PT)
Number of subjects: 0
Study 31094261 — intervention group
Group type: COMPARATOR
Intervention: Comparison of OPL vs PT
Number of subjects: 0
Study 30719774 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma coverage layer
Number of subjects: 180
Study 30719774 — intervention group
Group type: COMPARATOR
Intervention: Dartos flap
Number of subjects: 180
Study 28710339 — intervention group
Group type: EXPERIMENTAL
Intervention: CT screening
Number of subjects: 1546
Study 28710339 — intervention group
Group type: EXPERIMENTAL
Intervention: CT screening with additional clinical investigation
Number of subjects: 1546
Study 28710339 — intervention group
Group type: EXPERIMENTAL
Intervention: CT screening with negative result
Number of subjects: 1546
Study 28710339 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no screening)
Number of subjects: 1546
Study 26292720 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (ta‐VNS)
Number of subjects: 0
Study 26292720 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular non‐vagus nerve stimulation (tan‐VNS)
Number of subjects: 0
Study 26292720 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stimulation)
Number of subjects: 0
Study 24018915 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia-based surgical procedure manual (MMG)
Number of subjects: 101
Study 24018915 — intervention group
Group type: COMPARATOR
Intervention: Text-based surgical procedure manual (TG)
Number of subjects: 101
Study 21157359 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal suit (T‐Balance)
Number of subjects: 40
Study 21157359 — intervention group
Group type: COMPARATOR
Intervention: Conventional clothing (control)
Number of subjects: 40
Study 18349403 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation without cytotoxic treatment
Number of subjects: 340
Study 18349403 — intervention group
Group type: COMPARATOR
Intervention: Surgery or chemotherapy
Number of subjects: 340
Study 16574044 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrates
Number of subjects: 12249
Study 14674492 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 9
Study 14674492 — intervention group
Group type: COMPARATOR
Intervention: Open Flap Debridement (OFD)
Number of subjects: 9
Study 10762214 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 140
Study 10762214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 8609945 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of methotrexate (7.5 to 17.5 mg per week), sulfasalazine (500 mg twice daily), and hydroxychloroquine (200 mg twice daily)
Number of subjects: 102
Study 8609945 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone (7.5 to 17.5 mg per week)
Number of subjects: 102
Study 8609945 — intervention group
Group type: COMPARATOR
Intervention: Combination of sulfasalazine (500 mg twice daily) and hydroxychloroquine (200 mg twice daily)
Number of subjects: 102
Study 8272478 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirected use of pictures (art stimulation)
Number of subjects: 40
Study 8272478 — intervention group
Group type: COMPARATOR
Intervention: Control group (no art stimulation)
Number of subjects: 40
Study 3802705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (mean dose 32 mg/day)
Number of subjects: 60
Study 3802705 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (414 mg/day)
Number of subjects: 60
Study 3802705 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefruside added to nitrendipine or acebutolol
Number of subjects: 60
Study 3802705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine and Acebutolol (both treatments)
Number of subjects: 60
Study 3802705 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 60
Study 27895238 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate
Number of subjects: 65
Study 27895238 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading program (phonologically or strategy‐based reading instruction, or general academic strategy and social skills training)
Number of subjects: 65
Study 27895238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 25201932 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) training for PCPs
Number of subjects: 171
Study 25201932 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) training for PCPs (3 trainings)
Number of subjects: 171
Study 25201932 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients seen by MI‐trained PCPs
Number of subjects: 171
Study 25201932 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained PCPs)
Number of subjects: 171
Study 22229612 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal femoral nail antirotation (PFNA)
Number of subjects: 23
Study 22229612 — intervention group
Group type: COMPARATOR
Intervention: Reconstruction nail (Recon)
Number of subjects: 23
Study 20413522 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) intravenously at weeks 0, 2, 6, and 14
Number of subjects: 11
Study 20413522 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 11
Study 18403886 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (CHX)
Number of subjects: 110
Study 18403886 — intervention group
Group type: EXPERIMENTAL
Intervention: BioPure MTAD
Number of subjects: 110
Study 18403886 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.6% sodium hypochlorite (NaOCl)
Number of subjects: 110
Study 18403886 — intervention group
Group type: COMPARATOR
Intervention: Infected dentin tubes (positive control)
Number of subjects: 110
Study 18403886 — intervention group
Group type: COMPARATOR
Intervention: Sterile dentin tubes (negative control)
Number of subjects: 110
Study 16217977 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day telithromycin (800 mg once daily)
Number of subjects: 0
Study 16217977 — intervention group
Group type: COMPARATOR
Intervention: 10-day amoxicillin-clavulanate (500/125 mg 3 times daily)
Number of subjects: 0
Study 16217977 — intervention group
Group type: COMPARATOR
Intervention: 10-day cefuroxime axetil (250 mg twice daily)
Number of subjects: 0
Study 12016483 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma probe
Number of subjects: 150
Study 12016483 — intervention group
Group type: EXPERIMENTAL
Intervention: iPTH
Number of subjects: 150
Study 12016483 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither technique
Number of subjects: 150
Study 10228912 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Health Assessment (DynHA)
Number of subjects: 0
Study 10228912 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐36 and SF‐12 instruments
Number of subjects: 0
Study 10228912 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-based outcomes measure
Number of subjects: 0
Study 7757354 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased activities of glutamic‐pyruvic transaminase (GPT) and catalase
Number of subjects: 0
Study 7757354 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of GPT in women
Number of subjects: 0
Study 7757354 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher catalase activity in women
Number of subjects: 0
Study 7757354 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood serum catalase measurements
Number of subjects: 0
Study 1693714 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (2.5, 5, and 10 mg b.i.d. for 2 weeks each)
Number of subjects: 10
Study 1693714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 293045 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic systemic antibiotics
Number of subjects: 142
Study 293045 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotics)
Number of subjects: 142
Study 30681939 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced fat (RF)
Number of subjects: 18
Study 30681939 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3-enriched reduced fat (n-3RF)
Number of subjects: 18
Study 30681939 — intervention group
Group type: COMPARATOR
Intervention: Normal fat (NF)
Number of subjects: 18
Study 27951450 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense chemotherapy
Number of subjects: 1549
Study 27951450 — intervention group
Group type: COMPARATOR
Intervention: Standard-interval chemotherapy
Number of subjects: 1549
Study 26154930 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ cell infusion (1.0 x 10^7 cells/vessel)
Number of subjects: 38
Study 26154930 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ cell infusion (3.0 x 10^7 cells/vessel)
Number of subjects: 38
Study 23229239 — intervention group
Group type: EXPERIMENTAL
Intervention: CO₂ laser technique
Number of subjects: 48
Study 23229239 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery using cold knife
Number of subjects: 48
Study 22166738 — intervention group
Group type: EXPERIMENTAL
Intervention: Stoppa method
Number of subjects: 117
Study 22166738 — intervention group
Group type: COMPARATOR
Intervention: TEP method
Number of subjects: 117
Study 20090145 — intervention group
Group type: EXPERIMENTAL
Intervention: Odontic Microsystem treatment developed by R. Voll and R. Dale
Number of subjects: 100
Study 20090145 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex treatment for patients with inner organ pathology
Number of subjects: 100
Study 16446328 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral irinotecan (40 mg/m2/d MTD without cefixime; 60 mg/m2/d MTD with cefixime)
Number of subjects: 0
Study 16446328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (8 mg/kg/d beginning 5 days before irinotecan and continuing throughout the course)
Number of subjects: 0
Study 16446328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime with oral irinotecan
Number of subjects: 0
Study 16446328 — intervention group
Group type: COMPARATOR
Intervention: Oral irinotecan without cefixime
Number of subjects: 0
Study 16446328 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral irinotecan with cefixime
Number of subjects: 0
Study 15224273 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline treatment
Number of subjects: 93
Study 15224273 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 93
Study 11423921 — intervention group
Group type: COMPARATOR
Intervention: High-Fat Diet (HFD)
Number of subjects: 21
Study 11423921 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD)
Number of subjects: 21
Study 11423921 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Wine Supplementation (240 ml/day)
Number of subjects: 21
Study 9243749 — intervention group
Group type: EXPERIMENTAL
Intervention: Hep B-3 vaccine containing both preS1- and preS2-derived proteins in addition to hepatitis B surface antigen
Number of subjects: 86
Study 9243749 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B surface antigen vaccine
Number of subjects: 86
Study 7961239 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial injection of naloxone HCl (60 micrograms)
Number of subjects: 8
Study 7961239 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial vehicle (saline)
Number of subjects: 8
Study 7961239 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic infusion of naloxone (4 mg)
Number of subjects: 8
Study 7961239 — intervention group
Group type: COMPARATOR
Intervention: Systemic vehicle
Number of subjects: 8
Study 7961239 — intervention group
Group type: COMPARATOR
Intervention: Control (no naloxone or vehicle)
Number of subjects: 8
Study 7961239 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial naloxone
Number of subjects: 8
Study 7961239 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic naloxone
Number of subjects: 8
Study 7961239 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (saline)
Number of subjects: 8
Study 3591419 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 34
Study 3591419 — intervention group
Group type: EXPERIMENTAL
Intervention: Right unilateral ECT
Number of subjects: 34
Study 3591419 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosage, titrated ECT
Number of subjects: 34
Study 30158219 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with alcohol dependence
Number of subjects: 236
Study 30158219 — intervention group
Group type: COMPARATOR
Intervention: Individuals without alcohol dependence
Number of subjects: 236
Study 27544007 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-month dual-antiplatelet therapy (DAPT)
Number of subjects: 459
Study 27544007 — intervention group
Group type: COMPARATOR
Intervention: 6-month dual-antiplatelet therapy (DAPT)
Number of subjects: 459
Study 27544007 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically relevant bleeding (including Bleeding Academic Research Consortium type 3 or 5, TIMI, and GUSTO scales)
Number of subjects: 459
Study 27544007 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary ischemic endpoints (overall or cardiovascular mortality, myocardial infarction, stent thrombosis)
Number of subjects: 459
Study 24352823 — intervention group
Group type: EXPERIMENTAL
Intervention: I-ONE therapy administered postoperatively four hours per day for 60 days
Number of subjects: 33
Study 24352823 — intervention group
Group type: EXPERIMENTAL
Intervention: I-ONE therapy
Number of subjects: 33
Study 23498849 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU retinyl acetate every 6 months)
Number of subjects: 1000000
Study 23498849 — intervention group
Group type: COMPARATOR
Intervention: Control (no vitamin A supplementation)
Number of subjects: 1000000
Study 23498849 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 1000000
Study 20444849 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab in combination with capecitabine
Number of subjects: 0
Study 19040592 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril plus hydrochlorothiazide
Number of subjects: 11464
Study 19040592 — intervention group
Group type: COMPARATOR
Intervention: Benazepril plus amlodipine
Number of subjects: 11464
Study 16625329 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery alone (Treatment Arm A)
Number of subjects: 0
Study 16625329 — intervention group
Group type: COMPARATOR
Intervention: Surgery, then 1-hexylcarbamoyl-5-fluorouracil (Treatment Arm B)
Number of subjects: 0
Study 16625329 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery + 1-hexylcarbamoyl-5-fluorouracil + mitomycin C (Treatment Arm D)
Number of subjects: 0
Study 16625329 — intervention group
Group type: COMPARATOR
Intervention: Surgery, then 1-hexylcarbamoyl-5-fluorouracil (Treatment Arm C)
Number of subjects: 0
Study 16625329 — intervention group
Group type: EXPERIMENTAL
Intervention: Group W (well-differentiated adenocarcinoma)
Number of subjects: 0
Study 12794547 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose intrapartum neonatal nevirapine regimen
Number of subjects: 109
Study 10845685 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-emulsifying vitamin E preparation
Number of subjects: 0
Study 10845685 — intervention group
Group type: COMPARATOR
Intervention: Natopherol (commercial product)
Number of subjects: 0
Study 10845685 — intervention group
Group type: COMPARATOR
Intervention: Self-emulsifying vitamin E preparation and Natopherol
Number of subjects: 0
Study 8843210 — intervention group
Group type: EXPERIMENTAL
Intervention: Canarypox expressing HIV-1MN gp 160 followed by recombinant envelope protein boosts
Number of subjects: 20
Study 1640362 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental formulation of theophylline with 70% drum-dried corn starch (DDCS-70)
Number of subjects: 2
Study 1640362 — intervention group
Group type: COMPARATOR
Intervention: Theo-dur (reference sustained-release formulation)
Number of subjects: 2
Study 1640362 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental formulation with 50% starch
Number of subjects: 2
Study 6132612 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 100
Study 6132612 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 100
Study 6132612 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimeprazine
Number of subjects: 100
Study 6132612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30660722 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps strengthening intervention (10 sessions over 28 days)
Number of subjects: 53
Study 30409212 — intervention group
Group type: EXPERIMENTAL
Intervention: IIb preserving superselective neck dissection
Number of subjects: 32
Study 30409212 — intervention group
Group type: COMPARATOR
Intervention: Conventional supraomohyoid neck dissection
Number of subjects: 32
Study 30409212 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measured by FACT-HN version 4 questionnaire
Number of subjects: 32
Study 27782892 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment (5×10^9 CFU B. lactis B94)
Number of subjects: 71
Study 27782892 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic treatment (5×10^9 CFU B. lactis B94 and 900 mg inulin)
Number of subjects: 71
Study 27782892 — intervention group
Group type: COMPARATOR
Intervention: Prebiotic treatment (900 mg inulin)
Number of subjects: 71
Study 25251432 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose continuous (3 mg/kg q 24 hr)
Number of subjects: 24